PARAMUS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary continuous delivery technology, announced that the US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for STAR-OLZ in Chemotherapy Induced Nausea and Vomiting (CINV). STAR-OLZ is a multi-day transdermal delivery system (TDS) of olanzapine, covering the standard five day CINV treatment period. Independent double blinded studies have shown olanzapine to be a powerful antiemetic, with superiority in the control of nausea compared to other standard of care treatments, including NK1 receptor antagonists. Olanzapine is not approved for any nausea or vomiting indications.
The clinical development program is scheduled to advance in late 2022 with the launch of TROPIC-I, a Phase 2 dose-optimization study in HEC comparing STAR-OLZ an NK1-based triple-regimen with or without STAR-OLZ for CINV in approximately 120 cancer patients receiving highly emetogenic chemotherapy. The study is expected to enroll at an estimated 20+ clinical sites in the US. The study will assess STAR-OLZ superiority in Total Control (defined as no nausea, no vomiting, and no use of rescue medications) and no difference in the control of vomiting compared to the current treatment with combinations containing a 5-HT3, dexamethasone and NK1 antagonist.
“STAR-OLZ represents the first product to be developed for FDA approval using the Total Control primary endpoint, potentially improving outcomes and quality of life for patients,” said Dr. Jamie Oliver, Chief Medical Officer. “Total Control is a measure of no nausea, no vomiting, and no rescue medications; existing antiemetics have been approved using a Complete Response (CR) endpoint which only measures vomiting and the need for rescue medications.”
STAR-OLZ has previously completed Phase 1 in-human bioavailability (BA) studies which demonstrated the transdermal patch has acceptable local tolerability over the 5-day dosing interval and delivers approximately 60% less drug than the oral form.
About STAR-OLZ
Olanzapine has been shown to be a powerful antiemetic but is not approved for any nausea or vomiting indications. STAR-OLZ, a multi-day TDS delivery system of olanzapine has been evaluated using a disease-model challenge study to confirm the efficacious blood levels of the drug in nausea and vomiting and a healthy human volunteer study assessed the pharmacokinetics of TDS. STAR-OLZ is in development for two nausea and vomiting indications: CINV and PARP-inhibitor induced nausea and vomiting (PIINV).
CINV is among the most debilitating and feared side-effects of cancer treatment. Current guidelines recommend a three or four drug regimen to prevent CINV for the million people receiving highly emetogenic chemotherapy (HEC) each year in the US (American Cancer Society 2021); however, 60 to 70 percent still struggle with nausea (Chow 2021).
Starton licensed the rights to develop and commercialize STAR-OLZ in Mainland China to Haisco Pharmaceutical Group. The Company intends to retain the rights in the United States and is exploring partnerships in the rest of the world.
About Starton Therapeutics
A clinical-stage biotechnology company focused on transforming standard of care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, longer. Starton’s proprietary transdermal technology is intended to increase efficacy of approved drugs, to make them more tolerable and expand their potential use. To learn more visit www.startontx.com.
This press release contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as "may," "should," "plan," "intend," "potential," "continue," "believe," "expect," "predict," "anticipate" and "estimate," the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside the Company's control and involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on the Company's beliefs, assumptions and expectations of future performance, taking into account information currently available to the Company. Neither the Company nor any other person assumes responsibility for the accuracy or completeness of these statements. Information in this press release will be updated only to the extent required under applicable laws. If a change occurs, the Company’s business, financial condition, liquidity, results of operations, plans and objectives may vary materially from those expressed in the aforementioned forward-looking statements.
Starton Investor Relations:
investors@startontx.com
+1 551 287 6456
